Cocrystal Total Revenue vs Long Term Debt Analysis

COCP Stock

USD 1.98 0.02 1.02%

Cocrystal Pharma financial indicator trend analysis is way more than just evaluating Cocrystal Pharma prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Cocrystal Pharma is a good investment. Please check the relationship between Cocrystal Pharma Total Revenue and its Long Term Debt accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cocrystal Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.

To learn how to invest in Cocrystal Stock, please use our How to Invest in Cocrystal Pharma guide.

Total Revenue vs Long Term Debt

Total Revenue vs Long Term Debt Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Cocrystal Pharma Total Revenue account and Long Term Debt. At this time, the significance of the direction appears to have fragmental relationship.

The correlation between Cocrystal Pharma's Total Revenue and Long Term Debt is 0.52. Overlapping area represents the amount of variation of Total Revenue that can explain the historical movement of Long Term Debt in the same time period over historical financial statements of Cocrystal Pharma, assuming nothing else is changed. The correlation between historical values of Cocrystal Pharma's Total Revenue and Long Term Debt is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Revenue of Cocrystal Pharma are associated (or correlated) with its Long Term Debt. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Long Term Debt has no effect on the direction of Total Revenue i.e., Cocrystal Pharma's Total Revenue and Long Term Debt go up and down completely randomly.

Correlation Coefficient

0.52

Relationship Direction	Positive
Relationship Strength	Weak

View All Relationships

Total Revenue

Total revenue comprises all receipts Cocrystal Pharma generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.

Long Term Debt

Long-term debt is a debt that Cocrystal Pharma has held for over one year. Long-term debt appears on Cocrystal Pharma balance sheet and also includes long-term leases. The most common forms of long term debt are bonds payable, long-term notes payable, mortgage payable, pension liabilities, and lease liabilities. In the corporate world, long-term debt is generally used to fund big-ticket items, such as machinery, buildings, and land. The total of long-term debt reported on Cocrystal Pharma balance sheet is the sum of the balances of all categories of long-term debt. Debt that is not due within the current year and is often considered to be financing activities that are to be repaid over several years.

Most indicators from Cocrystal Pharma's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Cocrystal Pharma current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cocrystal Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.

To learn how to invest in Cocrystal Stock, please use our How to Invest in Cocrystal Pharma guide.At this time, Cocrystal Pharma's Enterprise Value Over EBITDA is relatively stable compared to the past year. As of 12/11/2024, Enterprise Value Multiple is likely to grow to 0.43, while Selling General Administrative is likely to drop slightly above 4.1 M.

	2021	2022	2023	2024 (projected)
Total Operating Expenses	14.2M	18.1M	3.4M	3.2M
Cost Of Revenue	239.5K	241.6K	15.2M	15.9M

Total Operating Expenses Cost Of Revenue

Cocrystal Pharma fundamental ratios Correlations

	Total Assets	Total Current Liabilities	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Other Stockholder Equity	Total Liab	Total Current Assets	Common Stock	Other Current Liab	Property Plant And Equipment Net	Other Current Assets	Property Plant And Equipment Gross	Short Long Term Debt Total	Net Receivables	Good Will	Non Current Liabilities Total	Inventory	Short Term Debt
Total Assets		0.17	0.58	0.03	0.2	0.24	-0.08	0.98	-0.41	-0.06	0.55	-0.09	-0.16	0.77	-0.1	0.57	0.3	-0.44	-0.28	-0.46	-0.43	-0.14	0.68	0.41	-0.45	0.34
Total Current Liabilities	0.17		-0.32	0.43	0.6	0.04	-0.41	0.24	0.05	-0.4	0.11	-0.37	-0.65	0.45	-0.35	0.14	0.86	0.18	0.48	0.01	0.16	-0.36	0.29	0.77	0.12	0.84
Total Stockholder Equity	0.58	-0.32		-0.21	-0.22	0.5	0.17	0.53	-0.67	0.16	0.68	0.14	0.53	-0.06	0.13	0.68	-0.23	-0.38	-0.26	-0.32	-0.51	0.12	0.5	-0.26	-0.51	-0.31
Net Debt	0.03	0.43	-0.21		0.75	0.05	-0.99	0.24	-0.14	-0.99	0.09	-0.8	-0.65	0.19	-0.99	0.13	0.28	0.05	-0.1	-0.33	0.48	0.33	0.33	0.26	0.44	0.45
Retained Earnings	0.2	0.6	-0.22	0.75		-0.08	-0.75	0.35	-0.11	-0.74	0.13	-0.51	-0.9	0.39	-0.74	0.23	0.47	-0.04	-0.06	-0.4	0.6	-0.17	0.31	0.47	0.6	0.76
Accounts Payable	0.24	0.04	0.5	0.05	-0.08		-0.02	0.24	-0.34	-0.02	0.41	-0.04	0.28	-0.08	-0.04	0.39	-0.2	0.34	-0.31	0.24	-0.01	-0.06	-0.04	-0.33	-0.05	-0.22
Cash	-0.08	-0.41	0.17	-0.99	-0.75	-0.02		-0.29	0.17	1.0	-0.12	0.8	0.65	-0.22	1.0	-0.17	-0.3	0.06	0.07	0.43	-0.42	-0.31	-0.4	-0.31	-0.38	-0.47
Non Current Assets Total	0.98	0.24	0.53	0.24	0.35	0.24	-0.29		-0.43	-0.27	0.55	-0.25	-0.29	0.78	-0.31	0.59	0.34	-0.44	-0.3	-0.53	-0.32	-0.07	0.73	0.45	-0.35	0.42
Non Currrent Assets Other	-0.41	0.05	-0.67	-0.14	-0.11	-0.34	0.17	-0.43		0.17	-0.96	0.18	-0.17	0.02	0.18	-0.96	0.02	0.24	0.1	0.3	0.16	-0.28	-0.43	0.09	0.19	0.03
Cash And Short Term Investments	-0.06	-0.4	0.16	-0.99	-0.74	-0.02	1.0	-0.27	0.17		-0.12	0.8	0.64	-0.19	1.0	-0.17	-0.29	0.06	0.07	0.42	-0.42	-0.32	-0.4	-0.29	-0.39	-0.46
Common Stock Total Equity	0.55	0.11	0.68	0.09	0.13	0.41	-0.12	0.55	-0.96	-0.12		-0.19	0.12	0.15	-0.13	0.98	0.15	-0.23	-0.04	-0.25	-0.23	0.11	0.46	0.07	-0.27	0.11
Common Stock Shares Outstanding	-0.09	-0.37	0.14	-0.8	-0.51	-0.04	0.8	-0.25	0.18	0.8	-0.19		0.46	-0.22	0.78	-0.15	-0.3	0.01	-0.11	0.15	-0.34	-0.4	-0.24	-0.27	-0.28	-0.41
Other Stockholder Equity	-0.16	-0.65	0.53	-0.65	-0.9	0.28	0.65	-0.29	-0.17	0.64	0.12	0.46		-0.59	0.64	0.04	-0.56	-0.02	0.0	0.28	-0.56	0.24	-0.18	-0.62	-0.55	-0.83
Total Liab	0.77	0.45	-0.06	0.19	0.39	-0.08	-0.22	0.78	0.02	-0.19	0.15	-0.22	-0.59		-0.21	0.17	0.55	-0.22	-0.15	-0.29	-0.14	-0.26	0.43	0.7	-0.17	0.65
Total Current Assets	-0.1	-0.35	0.13	-0.99	-0.74	-0.04	1.0	-0.31	0.18	1.0	-0.13	0.78	0.64	-0.21		-0.18	-0.25	0.08	0.14	0.45	-0.42	-0.31	-0.41	-0.26	-0.39	-0.44
Common Stock	0.57	0.14	0.68	0.13	0.23	0.39	-0.17	0.59	-0.96	-0.17	0.98	-0.15	0.04	0.17	-0.18		0.16	-0.28	-0.07	-0.36	-0.2	0.06	0.53	0.1	-0.23	0.17
Other Current Liab	0.3	0.86	-0.23	0.28	0.47	-0.2	-0.3	0.34	0.02	-0.29	0.15	-0.3	-0.56	0.55	-0.25	0.16		-0.25	0.65	-0.27	-0.14	-0.4	0.5	0.96	-0.19	0.91
Property Plant And Equipment Net	-0.44	0.18	-0.38	0.05	-0.04	0.34	0.06	-0.44	0.24	0.06	-0.23	0.01	-0.02	-0.22	0.08	-0.28	-0.25		-0.2	0.87	0.54	0.08	-0.67	-0.38	0.51	-0.23
Other Current Assets	-0.28	0.48	-0.26	-0.1	-0.06	-0.31	0.07	-0.3	0.1	0.07	-0.04	-0.11	0.0	-0.15	0.14	-0.07	0.65	-0.2		0.0	-0.26	-0.19	0.12	0.54	-0.28	0.41
Property Plant And Equipment Gross	-0.46	0.01	-0.32	-0.33	-0.4	0.24	0.43	-0.53	0.3	0.42	-0.25	0.15	0.28	-0.29	0.45	-0.36	-0.27	0.87	0.0		0.28	0.04	-0.76	-0.4	0.23	-0.36
Short Long Term Debt Total	-0.43	0.16	-0.51	0.48	0.6	-0.01	-0.42	-0.32	0.16	-0.42	-0.23	-0.34	-0.56	-0.14	-0.42	-0.2	-0.14	0.54	-0.26	0.28		0.03	-0.51	-0.2	0.98	0.17
Net Receivables	-0.14	-0.36	0.12	0.33	-0.17	-0.06	-0.31	-0.07	-0.28	-0.32	0.11	-0.4	0.24	-0.26	-0.31	0.06	-0.4	0.08	-0.19	0.04	0.03		0.02	-0.38	-0.02	-0.43
Good Will	0.68	0.29	0.5	0.33	0.31	-0.04	-0.4	0.73	-0.43	-0.4	0.46	-0.24	-0.18	0.43	-0.41	0.53	0.5	-0.67	0.12	-0.76	-0.51	0.02		0.55	-0.51	0.42
Non Current Liabilities Total	0.41	0.77	-0.26	0.26	0.47	-0.33	-0.31	0.45	0.09	-0.29	0.07	-0.27	-0.62	0.7	-0.26	0.1	0.96	-0.38	0.54	-0.4	-0.2	-0.38	0.55		-0.23	0.91
Inventory	-0.45	0.12	-0.51	0.44	0.6	-0.05	-0.38	-0.35	0.19	-0.39	-0.27	-0.28	-0.55	-0.17	-0.39	-0.23	-0.19	0.51	-0.28	0.23	0.98	-0.02	-0.51	-0.23		0.14
Short Term Debt	0.34	0.84	-0.31	0.45	0.76	-0.22	-0.47	0.42	0.03	-0.46	0.11	-0.41	-0.83	0.65	-0.44	0.17	0.91	-0.23	0.41	-0.36	0.17	-0.43	0.42	0.91	0.14

Click cells to compare fundamentals

Cocrystal Pharma Account Relationship Matchups

Cocrystal Pharma fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	28.5M	54.2M	79.4M	40.8M	31.3M	29.7M
Total Current Liabilities	2.3M	1.4M	1.5M	1.2M	3.3M	2.7M
Total Stockholder Equity	25.7M	52.5M	77.5M	39.6M	26.4M	42.6M
Net Debt	(6.6M)	(32.4M)	(58.2M)	(36.8M)	(24.5M)	(23.3M)
Retained Earnings	(235.3M)	(244.9M)	(259.1M)	(297.9M)	(315.9M)	(300.1M)
Accounts Payable	1.5M	657K	578K	614K	1.2M	931.8K
Cash	7.4M	33.0M	58.7M	37.1M	26.4M	27.7M
Non Current Assets Total	20.3M	20.2M	20.1M	662K	2.2M	2.1M
Non Currrent Assets Other	(293K)	40K	50K	46K	52.9K	55.5K
Cash And Short Term Investments	7.4M	33.0M	58.7M	37.1M	26.4M	27.7M
Common Stock Total Equity	24K	30K	36K	71K	81.7K	152.4K
Common Stock Shares Outstanding	31.9M	55.2M	88.4M	8.1M	9.7M	13.1M
Liabilities And Stockholders Equity	28.5M	54.2M	79.4M	40.8M	31.3M	29.7M
Other Stockholder Equity	260.9M	297.3M	336.5M	337.5M	342.3M	359.4M
Total Liab	2.8M	1.7M	1.8M	1.3M	4.9M	4.6M
Total Current Assets	8.3M	34.0M	59.3M	40.2M	29.1M	30.5M
Common Stock	36K	71K	98K	8K	10K	9.5K
Other Current Liab	7K	267K	495K	122K	1.6M	1.7M
Property Plant And Equipment Net	1.1M	1.1M	931K	616K	2.1M	2.2M
Other Current Assets	169K	449K	618K	2.3M	1.8M	948.7K
Property Plant And Equipment Gross	1.1M	1.1M	2.4M	2.2M	3.9M	4.1M
Short Long Term Debt Total	817K	596K	534K	297K	1.9M	1.6M
Non Current Liabilities Total	537K	379K	298K	57K	1.6M	1.5M
Short Term Debt	280K	434K	472K	480K	432K	410.4K
Net Tangible Assets	6.6M	33.4M	58.5M	39.6M	35.6M	34.6M
Other Assets	50K	544K	46K	0.0	1.0	0.95
Retained Earnings Total Equity	(138.0M)	(187.1M)	(235.3M)	(244.9M)	(220.4M)	(209.4M)
Capital Surpluse	243.4M	253.9M	260.9M	297.3M	341.9M	215.9M
Property Plant Equipment	1.1M	1.1M	931K	616K	708.4K	640.6K
Net Invested Capital	25.7M	52.5M	77.5M	39.6M	26.4M	45.1M

Pair Trading with Cocrystal Pharma

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cocrystal Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cocrystal Pharma will appreciate offsetting losses from the drop in the long position's value.

Moving together with Cocrystal Stock

0.61

BMY

Bristol Myers Squibb

Pair Corr

Moving against Cocrystal Stock

0.64	AMGN	Amgen Inc	Pair Corr
0.63	ABBV	AbbVie Inc	Pair Corr
0.6	TTOO	T2 Biosystms	Pair Corr
0.58	PFE	Pfizer Inc Fiscal Year End 4th of February 2025	Pair Corr
0.57	MRK	Merck Company Fiscal Year End 6th of February 2025	Pair Corr

The ability to find closely correlated positions to Cocrystal Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Cocrystal Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Cocrystal Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Cocrystal Pharma to buy it.

The correlation of Cocrystal Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cocrystal Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cocrystal Pharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Cocrystal Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Additional Tools for Cocrystal Stock Analysis

When running Cocrystal Pharma's price analysis, check to measure Cocrystal Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cocrystal Pharma is operating at the current time. Most of Cocrystal Pharma's value examination focuses on studying past and present price action to predict the probability of Cocrystal Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cocrystal Pharma's price. Additionally, you may evaluate how the addition of Cocrystal Pharma to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC